Stocks and Investing
Stocks and Investing
Mon, July 11, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Maintained (ADCT) at Strong Buy with Decreased Target to $44 on, Jul 11th, 2022
Robert Burns of HC Wainwright & Co., Maintained "ADC Therapeutics SA" (ADCT) at Strong Buy with Decreased Target from $54 to $44 on, Jul 11th, 2022.
Robert has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 0 agree with Robert's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Robert
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $30 on, Tuesday, May 10th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $17 on, Tuesday, May 10th, 2022
Contributing Sources